Breast Cancer Genetics and Indications for Prophylactic Mastectomy.
Abstract As more genetic information becomes available to inform breast cancer treatment, screening, and risk-reduction approaches, clinicians must become more knowledgeable about possible genetic testing and prevention strategies, including outcomes, benefits, risks, and limitations. The aim of this article is to define and distinguish high- and moderate-risk breast cancer predisposition genes, summarize the clinical recommendations that may be considered based on the identification of pathogenic variants (mutations) in these genes, and indications for risk-reducing and contralateral prophylactic mastectomy. ...
Source: Clinical Breast Cancer - July 15, 2018 Category: Cancer & Oncology Authors: Krontiras H, Farmer M, Whatley J Tags: Surg Clin North Am Source Type: research

Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System: Review of the Supporting Evidence.
Abstract The American Joint Committee on Cancer staging system has evolved in response to improved imaging, refined surgical techniques, enhanced pathologic evaluation, and greater understanding of tumor biology. The 8th edition has introduced clinical and pathologic prognostic stages for breast cancer that incorporate biologic variables (grade, estrogen/progesterone receptor status, HER2 status, multigene panels) with TNM categories that define the anatomic stage. The prognostic staging system facilitates more refined stratification than the anatomic stage with respect to survival and is an important advance that...
Source: Clinical Breast Cancer - July 15, 2018 Category: Cancer & Oncology Authors: Weiss A, King TA, Hunt KK, Mittendorf EA Tags: Surg Clin North Am Source Type: research

Impact of Advancing Technology on Diagnosis and Treatment of Breast Cancer.
Abstract New emerging breast imaging techniques have shown great promise in breast cancer screening, evaluation of extent of disease, and response to neoadjuvant therapy. Tomosynthesis, allows 3-dimensional imaging of the breast, and increases breast cancer detection. Fast abbreviated MRI has reduced time and costs associated with traditional breast MRI while maintaining cancer detection. Diffusion-weighted imaging is a functional MRI technique that does not require contrast and has shown potential in screening, lesion characterization and also evaluation of treatment response. New image-guided preoperative locali...
Source: Clinical Breast Cancer - July 15, 2018 Category: Cancer & Oncology Authors: Greenwood HI, Dodelzon K, Katzen JT Tags: Surg Clin North Am Source Type: research

Ductal Carcinoma In Situ.
Abstract Ductal carcinoma in situ has been stable in incidence for a decade and has an excellent prognosis. Breast conservation therapy is safe and effective for most patients. Adjuvant whole breast radiation therapy is recommended to reduce the risk of local recurrence. Accelerated partial breast irradiation is a promising alternative to decrease toxicity and improve cosmetic results. Adjuvant hormonal therapy can reduce local recurrence, but should be used cautiously. Future directions in management include developing predictive tools for guidance for use of adjuvant therapy and selecting low-risk patients ...
Source: Clinical Breast Cancer - July 15, 2018 Category: Cancer & Oncology Authors: Fu F, Gilmore RC, Jacobs LK Tags: Surg Clin North Am Source Type: research

Management of the Axilla in the  Patient with Breast Cancer.
Management of the Axilla in the Patient with Breast Cancer. Surg Clin North Am. 2018 Aug;98(4):747-760 Authors: Park KU, Caudle A Abstract Evaluation of the axillary lymph nodes is critical in the management of breast cancer because it is a key predictor of survival outcome. Surgeons must not only be able to perform sentinel lymph node dissection with high accuracy but also understand the implications of the results. Management of clinically node-negative and node-positive cases can vary significantly, as described in this review. With emerging data, management of the axilla in breast cancer will...
Source: Clinical Breast Cancer - July 15, 2018 Category: Cancer & Oncology Authors: Park KU, Caudle A Tags: Surg Clin North Am Source Type: research

Definition and Management of Positive Margins for Invasive Breast Cancer.
Abstract Breast-conserving surgery (BCS) followed by radiation therapy is the current standard of care for early stage breast cancer. Successful BCS necessitates complete tumor resection with clear margins at the pathologic assessment of the specimen ("no ink on tumor"). The presence of positive margins warrants additional surgery to obtain negative final margins, which has significant physical, psychological, and financial implications for the patient. The challenge lies in developing accurate real-time intraoperative margin assessment techniques to minimize the presence of "ink on tumor" and ...
Source: Clinical Breast Cancer - July 15, 2018 Category: Cancer & Oncology Authors: Nayyar A, Gallagher KK, McGuire KP Tags: Surg Clin North Am Source Type: research

Future Developments in Neoadjuvant Therapy for Triple-Negative Breast Cancer.
Abstract Breast cancer is the 2nd leading cause of cancer-related death in women in the United States. In general, advances in targeted treatment for breast cancer have improved over the last twenty years, except in the triple-negative breast cancer (TNBC) subtype. TNBC is an aggressive breast cancer subtype with limited treatment options as compared to hormone positive breast cancers. Recently, genomic profiling of TNBC shows promise in aiding clinicians to develop personalized targeted agents. Prioritizing novel molecular-based therapies in the neoadjuvant setting may help investigators understand mechanisms of ...
Source: Clinical Breast Cancer - July 15, 2018 Category: Cancer & Oncology Authors: Moore-Smith L, Forero-Torres A, Stringer-Reasor E Tags: Surg Clin North Am Source Type: research

Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer.
Abstract Inflammatory breast cancer (IBC) is a rare form of breast cancer that accounts for only 2% to 4% of all breast cancer cases. Despite its low incidence, IBC contributes to 7% to 10% of breast cancer caused mortality. Despite ongoing international efforts to formulate better diagnosis, treatment, and research, the survival of patients with IBC has not been significantly improved, and there are no therapeutic agents that specifically target IBC to date. The authors present a comprehensive overview that aims to assess the present and new management strategies of IBC. PMID: 30005774 [PubMed - in process] ...
Source: Clinical Breast Cancer - July 15, 2018 Category: Cancer & Oncology Authors: Menta A, Fouad TM, Lucci A, Le-Petross H, Stauder MC, Woodward WA, Ueno NT, Lim B Tags: Surg Clin North Am Source Type: research

The Evolving Role of Postmastectomy Radiation Therapy.
Abstract Throughout various eras of breast cancer therapy, postmastectomy radiation therapy (PMRT) has played an important role in the treatment of locally advanced breast cancer. PMRT decreases locoregional recurrence and may improve overall survival in patients with tumors over 5 cm or positive lymph nodes. As novel cancer therapies improve survival in breast cancer, the role of radiation therapy is evolving. Individualized recommendations for PMRT dependent on pathologic response after neoadjuvant systemic therapy are under investigation. This review summarizes the role of PMRT during breast cancer therapy...
Source: Clinical Breast Cancer - July 15, 2018 Category: Cancer & Oncology Authors: Everett AS, De Los Santos JF, Boggs DH Tags: Surg Clin North Am Source Type: research

Breast Cancer in the Elderly.
Abstract With increasing life expectancy and growth of the elderly US population, it becomes paramount that breast cancer research focuses more on the prevention, screening, and treatment of these patients. Age is no longer a cutoff for managing breast cancer in the elderly. Studies have shown the current undertreatment of cancer undermines survival, but the tide is turning to provide evidence-based medicine for the elderly. More often, clinicians and surgeons look not only at tumor-specific characteristics of breast cancer but also the functionality, tolerance, comorbidities, and life expectancy of patients to de...
Source: Clinical Breast Cancer - July 15, 2018 Category: Cancer & Oncology Authors: Varghese F, Wong J Tags: Surg Clin North Am Source Type: research

Evolution of Operative Technique for Mastectomy.
Abstract The radical mastectomy was the mainstay of breast cancer treatment through the majority of the twentieth century. However, as the understanding of breast cancer increased, the indications for more extensive surgical intervention decreased. The mastectomy has evolved so that skin-sparing or nipple-sparing mastectomy can be performed in the majority of women who undergo mastectomy currently. Today, nearly 40% of all women undergo mastectomy for breast cancer. The improved cosmetic appearance associated with skin- or nipple-sparing mastectomies does not compromise oncologic outcomes. PMID: 30005777 [Pub...
Source: Clinical Breast Cancer - July 15, 2018 Category: Cancer & Oncology Authors: Jones C, Lancaster R Tags: Surg Clin North Am Source Type: research

Role of Operative Management in Stage IV  Breast Cancer.
Role of Operative Management in Stage IV Breast Cancer. Surg Clin North Am. 2018 Aug;98(4):859-868 Authors: Teshome M Abstract The role of operative therapy in stage IV breast cancer continues to evolve with advances in therapy and improvements in survival among this population. Traditionally surgery was performed with palliative intent to alleviate symptoms related to the intact breast primary. Several retrospective studies have challenged this paradigm, demonstrating survival advantage with surgery in de novo metastatic disease. Prospective studies are ongoing and maturing data. A comprehensive...
Source: Clinical Breast Cancer - July 15, 2018 Category: Cancer & Oncology Authors: Teshome M Tags: Surg Clin North Am Source Type: research

Management of Breast Cancer.
PMID: 30005782 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 15, 2018 Category: Cancer & Oncology Authors: Parker CC Tags: Surg Clin North Am Source Type: research

Molecular biology as a tool for the treatment of cancer.
Abstract Cancer is a genetic disease characterized by uncontrolled cell growth and metastasis. Cancer can have a number of causes, such the activation of oncogenes, the inactivation of tumor-suppressing genes, mutagenesis provoked by external factors, and epigenetic modifications. The development of diagnostic tools and treatments using a molecular biological approach permits the use of sensitive, low-cost, noninvasive tests for cancer patients. Biomarkers can be used to provide rapid, personalized oncology, in particular the molecular diagnosis of chronic myeloid leukemia, and gastric, colon, and breast cancers. ...
Source: Clinical Breast Cancer - July 13, 2018 Category: Cancer & Oncology Authors: de Castro Sant' Anna C, Junior AGF, Soares P, Tuji F, Paschoal E, Chaves LC, Burbano RR Tags: Clin Exp Med Source Type: research

DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
Conclusion: Our data demonstrate that both DNA and histone modifications are involved in upregulation of PD-1, CTLA-4, TIM-3, and LAG-3 in breast tumor tissue and these epigenetic modifications could be useful as diagnostic/prognostic biomarkers and/or therapeutic targets in breast cancer. PMID: 29983831 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 11, 2018 Category: Cancer & Oncology Authors: Sasidharan Nair V, El Salhat H, Taha RZ, John A, Ali BR, Elkord E Tags: Clin Epigenetics Source Type: research

Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
reno F, Arrieta O Abstract Triple-negative breast cancer (TNBC) has been clinically difficult to manage because of tumor aggressiveness, cellular and histological heterogeneity, and molecular mechanisms' complexity. All this in turn leads us to evaluate that tumor biological behavior is not yet fully understood. Additionally, the heterogeneity of tumor cells represents a great biomedicine challenge in terms of the complex molecular-genetical-transcriptional and epigenetical-mechanisms, which have not been fully elucidated on human solid tumors. Recently, human breast cancer, but specifically TNBC is under basic an...
Source: Clinical Breast Cancer - July 11, 2018 Category: Cancer & Oncology Authors: Rodríguez Bautista R, Ortega Gómez A, Hidalgo Miranda A, Zentella Dehesa A, Villarreal-Garza C, Ávila-Moreno F, Arrieta O Tags: Clin Epigenetics Source Type: research

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis.
Abstract Cladribine Tablets (MAVENCLAD®) are used to treat relapsing multiple sclerosis (MS). The recommended dose is 3.5 mg/kg, consisting of 2 annual courses, each comprising 2 treatment weeks 1 month apart. We reviewed the clinical pharmacology of Cladribine Tablets in patients with MS, including pharmacokinetic and pharmacometric data. Cladribine Tablets are rapidly absorbed, with a median time to reach maximum concentration (Tmax) of 0.5 h (range 0.5-1.5 h) in fasted patients. When administered with food, absorption is delayed (median Tmax 1.5 h, range 1-3 h), and maximum con...
Source: Clinical Breast Cancer - July 10, 2018 Category: Cancer & Oncology Authors: Hermann R, Karlsson MO, Novakovic AM, Terranova N, Fluck M, Munafo A Tags: Clin Pharmacokinet Source Type: research

Safety of adipose-derived cell (stromal vascular fraction - SVF) augmentation for surgical breast reconstruction in cancer patients.
CONCLUSIONS: Our study does not produce any data suggesting increased cancer risk following breast reconstruction after a mastectomy or a lumpectomy combined with local radiotherapy. It may be concluded that an autologous transplantation of fat augmented with ASC is a safe and efficient procedure. Longer observation time and the observation of larger numbers of patients would be useful for strengthening the conclusion. PMID: 29989681 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 10, 2018 Category: Cancer & Oncology Authors: Mazur S, Zołocińska A, Siennicka K, Janik-Kosacka K, Chrapusta A, Pojda Z Tags: Adv Clin Exp Med Source Type: research

Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer Population.
Conclusion This large prospective study is the first to our knowledge of hsCRP as an inflammatory biomarker in RT-induced skin toxicities in breast cancer. We demonstrate that nonobese patients with elevated RT-related change in hsCRP levels have a significantly increased risk of grade 4+ skin toxicity. The outcomes may help to predict RT responses and guide decision making. PMID: 29989859 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 10, 2018 Category: Cancer & Oncology Authors: Hu JJ, Urbanic JJ, Case LD, Takita C, Wright JL, Brown DR, Langefeld CD, Lively MO, Mitchell SE, Thakrar A, Bryant D, Baglan K, Strasser J, Baez-Diaz L, Lesser GJ, Shaw EG Tags: J Clin Oncol Source Type: research

Breast tumour resembling tall cell variant of papillary thyroid carcinoma: case presentation (in a patient with Lynch syndrome).
PMID: 29982234 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 7, 2018 Category: Cancer & Oncology Authors: Gai L, Done SJ, Cook D, Denic N, Erivwo P, Voisey K, Kao K Tags: J Clin Pathol Source Type: research

Providing integrative care in the pre-chemotherapy setting: a pragmatic controlled patient-centered trial with implications for supportive cancer care.
CONCLUSION: A patient-tailored CIM program, initiated within a week of the first chemotherapy cycle, may help reduce the severity of fatigue, depression, and impaired well-being among patients with breast and gynecological cancers. PMID: 29980837 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 6, 2018 Category: Cancer & Oncology Authors: Ben-Arye E, Dahly H, Keshet Y, Dagash J, Samuels N Tags: J Cancer Res Clin Oncol Source Type: research

Periodontal disease and susceptibility to breast cancer: a meta-analysis of observational studies.
CONCLUSION: Our results provided evidence of a modest positive association between periodontal disease and breast cancer. Implementation of practical measures to prevent and treat periodontal disease is of great public health significance. Moreover, additional studies are recommended to explore this topic in more detail. This article is protected by copyright. All rights reserved. PMID: 29974484 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 5, 2018 Category: Cancer & Oncology Authors: Shi T, Min M, Sun C, Zhang Y, Liang M, Sun Y Tags: J Clin Periodontol Source Type: research

Correction to: Reply to the letter "Cardiac autonomic evaluation in breast cancer patients: role of cytokines and heart rate recovery".
Correction to: Reply to the letter "Cardiac autonomic evaluation in breast cancer patients: role of cytokines and heart rate recovery". Clin Res Cardiol. 2018 Jul 03;: Authors: Arab C, Vanderlei LCM, Gidron Y, Ferreira C Abstract Unfortunately, errors occurred in the original article. PMID: 29971564 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 3, 2018 Category: Cancer & Oncology Authors: Arab C, Vanderlei LCM, Gidron Y, Ferreira C Tags: Clin Res Cardiol Source Type: research

Drug-Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers.
This article is protected by copyright. All rights reserved. PMID: 29972633 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 3, 2018 Category: Cancer & Oncology Authors: Bashir B, Stickle DF, Chervoneva I, Kraft WK Tags: Clin Transl Sci Source Type: research

Is an indistinct picture "exactly what we need"? Objectivity, accuracy, and harm in imaging for cancer.
Is an indistinct picture "exactly what we need"? Objectivity, accuracy, and harm in imaging for cancer. J Eval Clin Pract. 2018 Jul 02;: Authors: Reid L Abstract Assumptions about the epistemic ideal of objectivity, closely related to ontological assumptions about the nature of disease as pathophysiological abnormality, lead us into oversimplified ways of thinking about medical imaging. This is illustrated by current controversies in the early detection of cancer. Improvements in the technical quality of imaging failed to address the problem of overdiagnosis in breast cancer screening and ex...
Source: Clinical Breast Cancer - July 2, 2018 Category: Cancer & Oncology Authors: Reid L Tags: J Eval Clin Pract Source Type: research

The dark side of granulocyte-colony stimulating factor: a supportive therapy with potential to promote tumour progression.
Abstract Granulocyte-colony stimulating factor (G-CSF) is one of several cytokines that can expand and mobilize haematopoietic precursor cells from bone marrow. In particular, G-CSF mobilizes neutrophils when the host is challenged by infection or tissue damage. Severe neutropenia, or febrile neutropenia is a life-threatening event that can be mitigated by administration of G-CSF. Consequently, G-CSF has been used to support patients undergoing chemotherapy who would otherwise require dose reduction due to neutropenia. Over the past 10-15 years it has become increasingly apparent, in preclinical tumour growth...
Source: Clinical Breast Cancer - July 2, 2018 Category: Cancer & Oncology Authors: Yeo B, Redfern AD, Mouchemore KA, Hamilton JA, Anderson RL Tags: Clin Exp Metastasis Source Type: research

Therapeutic effect of simvastatin on DMBA-induced breast cancer in mice.
This article is protected by copyright. All rights reserved. PMID: 29962034 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - July 1, 2018 Category: Cancer & Oncology Authors: Karimi B, Ashrafi M, Shomali T, Yektaseresht A Tags: Fundam Clin Pharmacol Source Type: research

Breast cancer incidence rates in the world from the Cancer Incidence in Five Continents XI.
PMID: 29931296 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 28, 2018 Category: Cancer & Oncology Authors: Katanoda K, Hori M Tags: Jpn J Clin Oncol Source Type: research

Hormonal Management for Transfeminine Individuals.
Abstract Transfeminine individuals are treated with estradiol and anti-androgen agents to transition to a more feminine appearance. The physical changes that occur with estradiol therapy include breast development, body fat redistribution, and decreased muscle mass. Transfeminine treatment regimens require monitoring and dose adjustments to achieve appropriate physiologic targets to enhance feminization and decrease risk of adverse outcomes. Adverse effects associated with estradiol use include thromboembolic disease, macroprolactinoma, breast cancer, coronary artery disease, cerebrovascular disease, cholelithiasi...
Source: Clinical Breast Cancer - June 18, 2018 Category: Cancer & Oncology Authors: Abramowitz J, Tangpricha V Tags: Clin Plast Surg Source Type: research

Primary breast cancer relapse as metastasis to the cervix uteri: A case report.
Abstract Metastasis of non-gynaecological tumours to the cervix is a rare event, and metastasis from breast cancer is even rarer, with only a limited number of such cases reported in the literature to date. We herein report the case of an 86-year-old female patient who had undergone mastectomy and axillary lymphadenectomy for invasive ductal cell breast carcinoma 2 years prior, followed by adjuvant hormonal therapy with letrozole. During hospitalization for anemia associated with an inflammatory syndrome and abdominal pain with menorrhagia, an abdominal ultrasound examination revealed a suspicious uterine mass wit...
Source: Clinical Breast Cancer - June 14, 2018 Category: Cancer & Oncology Authors: Thouvenot A, Bizet Y, Baccar LS, Lamuraglia M Tags: Mol Clin Oncol Source Type: research

Incidence and Factors Associated With Attentional Fatigue in Working Long-term Breast Cancer Survivors.
Abstract PURPOSE: The purpose of this study was to examine the incidence of attentional fatigue and the relationship between sleep disturbance and attentional fatigue in working long-term breast cancer survivors (BCS). METHODS: A descriptive, correlation design was used. The data for this study were drawn from a larger descriptive study designed to understand the impact of cognitive dysfunction on work-related outcomes. Breast cancer survivors completed questionnaires regarding sleep disturbance, attentional fatigue, and demographic and medical characteristics. Sleep disturbance, a subscale of the Pittsburgh ...
Source: Clinical Breast Cancer - June 8, 2018 Category: Cancer & Oncology Authors: Crouch A, Von Ah D Tags: Clin Nurse Spec Source Type: research

siRNA-mediated silencing of CDK8 inhibits proliferation and growth in breast cancer cells [Retraction].
Authors: Abstract [This retracts the article on p. 92 in vol. 7, PMID: 24427329.]. PMID: 29874337 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 7, 2018 Category: Cancer & Oncology Tags: Int J Clin Exp Pathol Source Type: research

Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review.
Abstract Subsequent malignant neoplasms (SMNs) in childhood cancer survivors cause substantial morbidity and mortality. This review summarizes recent literature on SMN epidemiology, risk factors, surveillance, and interventions. Survivors of childhood cancer experience long-term increased SMN risk compared with the general population, with a greater than twofold increased solid tumor risk extending beyond age 40 years. There is a dose-dependent increased risk for solid tumors after radiotherapy, with the highest risks for tumors occurring in or near the treatment field (eg, greater than fivefold increased risk for...
Source: Clinical Breast Cancer - June 6, 2018 Category: Cancer & Oncology Authors: Turcotte LM, Neglia JP, Reulen RC, Ronckers CM, van Leeuwen FE, Morton LM, Hodgson DC, Yasui Y, Oeffinger KC, Henderson TO Tags: J Clin Oncol Source Type: research

Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients.
JP Abstract PURPOSE: Cardiotoxicity is the most important side effect of trastuzumab treatment. Heart function monitoring is recommended during the treatment which has led to growing use of resources. The aim of this retrospective study was to determine the frequency and timing of trastuzumab cardiotoxicity and its risk factors in real-world setting. METHODS: Single institute, retrospective collection of data on HER2+ breast cancer patients (n = 246) was carried out through a pharmacy search for patients who had received trastuzumab in 2006-2014. Clinical and pathological factors, treatment his...
Source: Clinical Breast Cancer - June 5, 2018 Category: Cancer & Oncology Authors: Moilanen T, Jokimäki A, Tenhunen O, Koivunen JP Tags: J Cancer Res Clin Oncol Source Type: research

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
lem G Abstract Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy in the advanced setting. Patients and Methods Patients were randomly assigned at a two-to-one ratio to ribociclib plus fulvestrant or placebo plus fulvestrant. The primary end point was locally assessed progression-free survival. Secondary end points included overall survival, overall response rate, and safety. Results A total of 484...
Source: Clinical Breast Cancer - June 3, 2018 Category: Cancer & Oncology Authors: Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G Tags: J Clin Oncol Source Type: research

Tamoxifen and the risk of Parkinsonism: a case/non-case study.
CONCLUSION: This study did not find evidence for Parkinsonism associated with tamoxifen. PMID: 29862427 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 3, 2018 Category: Cancer & Oncology Authors: Montastruc F, Khosrow-Khavar F, de Germay S, Renoux C, Rousseau V, Durrieu G, Montastruc M, Rascol O, Sommet A, Lapeyre-Mestre M, Benevent J, Montastruc JL Tags: Eur J Clin Pharmacol Source Type: research

Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
Abstract AIMS: To fully elucidate the clinicopathological features of breast carcinoma in sclerosing adenosis (SA-BC). METHODS: Clinical and histological characteristics of 206 SA-BCs from 180 patients were retrospectively evaluated. Immunohistochemical phenotype was examined. The clinicopathological relevance of the topographical pattern of SA-BCs was analysed. RESULTS: Overall, up to 46 patients (25.6%) had contralateral cancer, either SA associated or not. Of 99 cases who underwent core needle biopsy (CNB), 36 were underestimated as adenosis or atypical ductal hyperplasia at CNB, 5 invasive cases were...
Source: Clinical Breast Cancer - June 1, 2018 Category: Cancer & Oncology Authors: Yu BH, Tang SX, Xu XL, Cheng YF, Bi R, Shui RH, Tu XY, Lu HF, Zhou XY, Yang WT Tags: J Clin Pathol Source Type: research

Use of antipsychotics and risk of breast cancer: A Danish nationwide case-control study.
CONCLUSIONS: Overall, our results do not suggest a clinically important association between antipsychotic use and risk of breast cancer. The importance of drug-induced prolactin elevation is unclear but may lead slightly increased risk of estrogen receptor positive breast cancer. PMID: 29858518 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 1, 2018 Category: Cancer & Oncology Authors: Pottegård A, Lash TL, Cronin-Fenton D, Ahern TP, Damkier P Tags: Br J Clin Pharmacol Source Type: research

Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies.
Abstract Background Pegfilgrastim is widely used for prophylaxis of febrile neutropenia (FN) in cancer patients receiving chemotherapies. However, the optimal timing of pegfilgrastim administration has not been established. Objective We investigated the effect of the timing of pegfilgrastim administration on the prevention of FN in patients with breast cancer undergoing intermediate-risk chemotherapies. Method We retrospectively analysed the incidence of FN in patients with breast cancer treated at our institution with intermediate-risk chemotherapies and primary or secondary prophylactic pegfilgrastim between 201...
Source: Clinical Breast Cancer - June 1, 2018 Category: Cancer & Oncology Authors: Hayama T, Sakurai K, Miura K, Washinosu S, Tsuboi S, Uchiike A, Yoshida Y, Takei M Tags: Int J Clin Pharm Source Type: research

Breast Carcinoma: Updates in Molecular Profiling 2018.
Abstract The most significant contribution of molecular subtyping of breast carcinomas has been the identification of estrogen-positive and estrogen-negative tumor subtypes. Knowledge of genetic alterations in these tumors will help clinicians identify novel therapeutic targets. Understanding the progression pathways involved in the transition of in situ carcinoma to invasive carcinoma might lead to efficient risk stratification in these patients. The Cancer Genome Analysis Network has collected genomic and epigenomic data to provide comprehensive information regarding carcinogenesis and pathway interactions....
Source: Clinical Breast Cancer - May 22, 2018 Category: Cancer & Oncology Authors: Bandyopadhyay S, Bluth MH, Ali-Fehmi R Tags: Clin Lab Med Source Type: research

Comprehensive Geriatric Assessment: Interprofessional Team Recommendations for Older Adult Women With Breast Cancer.
Abstract BACKGROUND: Geriatric oncology incorporates comprehensive geriatric assessment (CGA) and traditional oncology care. OBJECTIVES: The aims are to identify limitations reflected by mean scores on the CGA instruments and describe the CGA recommendations documented in the medical record. METHODS: CGA was administered and consisted of the Timed Up and Go Test, the Activities of Daily Living Scale, the Instrumental Activities of Daily Living Scale, grip strength, falls, pain, the Brief Fatigue Inventory, the Pittsburgh Sleep Quality Index, the Geriatric Depression Scale, the Mini-Cog, and the Mini Nutr...
Source: Clinical Breast Cancer - May 22, 2018 Category: Cancer & Oncology Authors: Overcash J Tags: Clin J Oncol Nurs Source Type: research

Previvor: An Oncology Nurse's Story of Cancer Risk Reduction Through Genetic Testing.
Abstract My mother was diagnosed with triple-negative breast cancer in 1998 at age 48. Her younger sister has been diagnosed with breast cancer at age 33 but ultimately died of ovarian cancer at age 47. Her mother died of ovarian cancer at age 47. I knew my fate. Meanwhile, as the medical world around me kept turning, the medical-surgical floor on which I worked became an oncology floor. This was not part of my plan. PMID: 29781468 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 22, 2018 Category: Cancer & Oncology Authors: Kelly J Tags: Clin J Oncol Nurs Source Type: research

Cognitive Changes: Educating Breast Cancer Survivors With the Think Well: Healthy Living to Improve Cognitive Function Program.
Abstract Cognitive changes may occur after cancer treatment and interfere with day-to-day activities of breast cancer survivors. Current guidelines recommend validating cognitive concerns, increasing patient education, and suggesting appropriate interventions. Educational programs, including Think Well: Healthy Living to Improve Cognitive Function, can increase the awareness of cognitive changes and provide strategies for self-management to breast cancer survivors and their family and friends. PMID: 29781472 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 22, 2018 Category: Cancer & Oncology Authors: Vo JB, Nolan TS, Bail JR, Gisiger-Camata S, Meneses K Tags: Clin J Oncol Nurs Source Type: research

Retraction Note to: The BRCA2 variant c.68-7  T  >  A is associated with breast cancer.
Retraction Note to: The BRCA2 variant c.68-7 T > A is associated with breast cancer. Hered Cancer Clin Pract. 2018;16:10 Authors: Møller P, Hovig E Abstract [This retracts the article DOI: 10.1186/s13053-017-0080-y.]. PMID: 29745381 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 12, 2018 Category: Cancer & Oncology Authors: Møller P, Hovig E Tags: Hered Cancer Clin Pract Source Type: research

Cancer in Pregnancy.
This article reviews some of the more common types of cancer that may be encountered during pregnancy. It reviews the unique challenges with the diagnosis and treatment of breast, cervical, hematologic, and colon cancers in pregnant patients. PMID: 29747725 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 12, 2018 Category: Cancer & Oncology Authors: McCormick A, Peterson E Tags: Obstet Gynecol Clin North Am Source Type: research

Hormone Therapy in Breast Cancer Survivors and Those at High Risk for Breast Cancer.
Abstract Women and health care providers are often fearful of using hormone therapy to deal with distressing menopausal symptoms in circumstances where there is a perceived or real increased risk of breast cancer. This paper examines the evidence for and against hormone therapy use in 3 common clinical situations: the woman with a positive family history in a first-degree relative, the woman who has undergone risk-reducing salpingo-oophorectomy due to a known genetic mutation, and the woman in whom treatment of breast cancer has induced premature menopause. PMID: 29750683 [PubMed - as supplied by publisher] (...
Source: Clinical Breast Cancer - May 10, 2018 Category: Cancer & Oncology Authors: Reid RL Tags: Clin Obstet Gynecol Source Type: research

SPIN1, negatively regulated by miR-148/152, enhances Adriamycin resistance via upregulating drug metabolizing enzymes and transporter in breast cancer.
CONCLUSIONS: Our results establish that SPIN1, negatively regulated by the miR-148/152 family, enhances Adriamycin resistance in breast cancer via upregulating the expression of drug metabolizing enzymes and drug transporter. PMID: 29743122 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 9, 2018 Category: Cancer & Oncology Authors: Chen X, Wang YW, Gao P Tags: J Exp Clin Cancer Res Source Type: research

Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study.
CONCLUSION: PLAC-B as neoadjuvant treatment of this subpopulation with TNBC and ER/PR+ patients is effective and safe. Further studies are necessitated. PMID: 29744672 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 9, 2018 Category: Cancer & Oncology Authors: Tampaki EC, Tampakis A, Alifieris CE, Krikelis D, Pazaiti A, Kontos M, Trafalis DT Tags: Clin Drug Investig Source Type: research

Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
CONCLUSIONS: Once-daily seviteronel was generally well tolerated in women with and 450 mg QD was chosen as the RP2D. PMID: 29744674 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 9, 2018 Category: Cancer & Oncology Authors: Bardia A, Gucalp A, DaCosta N, Gabrail N, Danso M, Ali H, Blackwell KL, Carey LA, Eisner JR, Baskin-Bey ES, Traina TA Tags: Breast Cancer Res Treat Source Type: research

Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia.
Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia. Clin Endocrinol (Oxf). 2018 May 09;: Authors: Grossmann M, Ramchand S, Milat F, Vincent A, Lim E, Kotowicz MA, Hicks J, Teede H Abstract OBJECTIVE: To formulate clinical consensus recommendations on bone health assessment and management of women with oestrogen receptor-positive ear...
Source: Clinical Breast Cancer - May 9, 2018 Category: Cancer & Oncology Authors: Grossmann M, Ramchand S, Milat F, Vincent A, Lim E, Kotowicz MA, Hicks J, Teede H Tags: Clin Endocrinol (Oxf) Source Type: research